The combination of trastuzumab (Herceptin) and tucatinib (Tukysa) has been approved by the FDA (Food and Drug Administration) for the treatment of HER2-positive, RAS wild-type metastatic CRC following prior chemotherapy, based on the results of the MOUNTAINEER trial [54]. The gene discussed is ERBB2; the disease is colorectal carcinoma.